EXACT Sciences Corporation (EXAS) - Total Liabilities
Based on the latest financial reports, EXACT Sciences Corporation (EXAS) has total liabilities worth $3.46 Billion USD as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore EXAS shareholders equity momentum to track the company's year-over-year net asset growth rate.
EXACT Sciences Corporation - Total Liabilities Trend (1998–2025)
This chart illustrates how EXACT Sciences Corporation's total liabilities have evolved over time, based on quarterly financial data. See EXAS cash flow after capex ratio to measure how efficiently the company converts operating cash flow to free cash.
EXACT Sciences Corporation Competitors by Total Liabilities
The table below lists competitors of EXACT Sciences Corporation ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
HP Inc
NYSE:HPQ
|
USA | $38.13 Billion |
|
Royal Gold Inc
NASDAQ:RGLD
|
USA | $2.03 Billion |
|
Allegheny Technologies Incorporated
NYSE:ATI
|
USA | $3.18 Billion |
|
China United Network Communications Ltd
SHG:600050
|
China | CN¥291.69 Billion |
|
China Merchants Securities Co Ltd
SHG:600999
|
China | CN¥627.92 Billion |
|
Rongsheng Petrochemical Co Ltd
SHE:002493
|
China | CN¥296.47 Billion |
|
Kyocera Corporation
F:KYRA
|
Germany | €1.20 Trillion |
|
Ruijie Networks Co. Ltd. A
SHE:301165
|
China | CN¥4.67 Billion |
Liability Composition Analysis (1998–2025)
This chart breaks down EXACT Sciences Corporation's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see EXACT Sciences Corporation market cap and net worth.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 2.23 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 1.44 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.59 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how EXACT Sciences Corporation's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for EXACT Sciences Corporation (1998–2025)
The table below shows the annual total liabilities of EXACT Sciences Corporation from 1998 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $3.46 Billion | -1.88% |
| 2024-12-31 | $3.53 Billion | +6.01% |
| 2023-12-31 | $3.33 Billion | +4.47% |
| 2022-12-31 | $3.18 Billion | -3.44% |
| 2021-12-31 | $3.30 Billion | +22.60% |
| 2020-12-31 | $2.69 Billion | +120.87% |
| 2019-12-31 | $1.22 Billion | +44.44% |
| 2018-12-31 | $843.08 Million | +978.91% |
| 2017-12-31 | $78.14 Million | +87.19% |
| 2016-12-31 | $41.74 Million | +11.50% |
| 2015-12-31 | $37.44 Million | +65.37% |
| 2014-12-31 | $22.64 Million | +100.16% |
| 2013-12-31 | $11.31 Million | -16.36% |
| 2012-12-31 | $13.52 Million | +0.49% |
| 2011-12-31 | $13.46 Million | -19.71% |
| 2010-12-31 | $16.76 Million | -14.82% |
| 2009-12-31 | $19.68 Million | +136.18% |
| 2008-12-31 | $8.33 Million | +0.29% |
| 2007-12-31 | $8.31 Million | -6.77% |
| 2006-12-31 | $8.91 Million | -32.62% |
| 2005-12-31 | $13.22 Million | -27.05% |
| 2004-12-31 | $18.13 Million | -19.26% |
| 2003-12-31 | $22.45 Million | +91.30% |
| 2002-12-31 | $11.74 Million | +183.95% |
| 2001-12-31 | $4.13 Million | +204.22% |
| 2000-12-31 | $1.36 Million | +295.10% |
| 1999-12-31 | $343.89K | -16.12% |
| 1998-12-31 | $410.00K | -- |
About EXACT Sciences Corporation
Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. It offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer; Cologuard Plus Tests; Cancerguard Test; and Genetic Testing. The company also provides Oncotype DX Breast Recurrence S… Read more